Actively Recruiting
Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL)
Led by Beijing Sanbo Brain Hospital · Updated on 2024-10-15
21
Participants Needed
1
Research Sites
254 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is intend to improve the objective response rate in treatment of camrelizumab in recurrent primary central nervous system lymphoma patients.
CONDITIONS
Official Title
Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Initial diagnosis of primary diffuse large B-cell lymphoma of the CNS confirmed by histopathology
- Tumor recurrence confirmed by MRI after first-line methotrexate-based treatment
- Measurable tumor focus on MRI larger than 10x10 mm
- Age over 18 years
- Life expectancy of at least 12 weeks
- Karnofsky performance status of at least 50%
- Normal function of main organs without serious blood, heart, lung, liver, kidney, or immune deficiency diseases
- Specific lab values: white blood cells >3.0x10^9/L; platelets >80x10^9/L; hemoglobin >10 g/dL; serum bilirubin ≤1.5 times upper limit of normal; ALT and AST ≤2 times upper limit of normal; serum creatinine ≤1.5 mg/dL
- Female participants of childbearing age must not be pregnant and agree to use effective contraception during the study and for 3 months after
- Willingness to participate and sign informed consent
You will not qualify if you...
- Receiving any other anti-tumor therapy concurrently
- Allergy to components of the study drug
- Prior treatment with anti-PD-1, anti-PD-L1, or anti-PD-L2 agents
- Active or history of autoimmune diseases such as autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, pituitary inflammation, vasculitis, nephritis, or thyroid disorders
- Use of systemic steroids or immunosuppressive therapy within 7 days before trial treatment, except stable or decreasing low-dose dexamethasone for brain edema
- Active infection
- Risk of bleeding
- HIV positive status
- Pregnancy or breastfeeding
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sanbo Brain Hospital Capital Medical University
Beijing, China
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here